亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

Drug discovery based on Alzheimer's disease mutations

總結: Lead Inventors: Iva Greenwald, Ph.D.Problem or Unmet Need:Alzheimer's disease is a devastating disease afflicting millions, and its prevalence is rapidly increasing. Although a number of treatments are available, they function almost exclusively to palliate symptoms, rather than reverse damage or halt disease progression. A number of common and rare genetic mutations have been associated with the disease, and these are promising targets for drug development. In particular, mutations of presenilin 1 and 2 have been associated with familial early-onset AD, inherited in an autosomal dominant manner. In these cases, the alteration of presenilin's function leads to the excessive accumulation of amyloid-beta that is synonymous with AD. The inventors have discovered and characterized two genes, hop-1 and sel-12, in C. elegans that display high homology to human presenilins. The inventors then created mutations in these genes homologous to those that cause AD in humans. These mutations lead to an observable phenotype, constitutive egg-laying. This phenotype can then be utilized as a screening mechanism to identify novel compounds that may be useful in treating AD.

技術優勢: Organism-based screen: using a phenotypic screen can identify drug candidates that would be missed in protein target-based screens High-throughput: C. elegans is the multicellular model organisms best suited for high-throughput screening

技術應用: Novel target and biological screen for Alzheimer's drug development Sequence data and antibodies may be useful for development of Alzheimer's diagnostics

詳細技術說明: The inventors have discovered and characterized two genes, hop-1 and sel-12, in C. elegans that display high homology to human presenilins. The inventors then created mutations in these genes homologous to those that cause AD in humans. These mutatio...

*Inquiry: Peter Golikov Columbia Technology Ventures Tel: (212) 854-8444 Email: TechTransfer@columbia.edu

*Publications: Levitan D, Doyle TG, Brousseau D, Lee MK, Thinakaran G, Slunt HH, Sisodia SS, Greenwald I. Assessment of normal and mutant human presenilin function in Caenorhabditis elegans. Proc Natl Acad Sci U S A. (1996) Dec 10;93(25):14940-4.

欲了解更多信息，請點擊這裡